Peter Verdult
Stock Analyst at Exane BNP Paribas
(4.01)
# 1,761
Out of 4,649 analysts
208
Total ratings
61.1%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Peter Verdult
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Downgraded: Hold | $50 | $43.72 | +14.36% | 3 | Apr 20, 2026 | |
| RHHBY Roche Holding AG | Downgraded: Hold | $50 | $54.52 | -8.29% | 1 | Mar 17, 2026 | |
| NVO Novo Nordisk | Upgraded: Hold | $61 → $54 | $45.89 | n/a | 4 | Aug 13, 2025 | |
| LON: 0NZT UCB SA | Maintained: Buy | €182.00 | €215.55 | n/a | 32 | Jun 27, 2025 | |
| LON: AZN AstraZeneca PLC | Initiated Coverage: Buy | 14,000p → 11,500p | 11,460p | n/a | 7 | Apr 16, 2025 | |
| LON: GSK GSK plc | Initiated Coverage: Hold | 1,900p → 1,350p | 1,818p | n/a | 7 | Apr 16, 2025 | |
| EPA: IPN Ipsen S.A. | Initiated Coverage: Hold | €100.00 | €156.00 | n/a | 1 | Apr 16, 2025 | |
| ETR: MRK Merck KGaA | Initiated Coverage: Sell | €190.00 → €107.00 | €136.30 | n/a | 10 | Apr 16, 2025 | |
| SWX: ROP Roche Holding AG | Initiated Coverage: Buy | CHF 335.00 → CHF 300.00 | CHF 355.10 | n/a | 4 | Apr 16, 2025 | |
| SWX: NOVN Novartis AG | Initiated Coverage: Buy | CHF 97.00 → CHF 95.00 | CHF 122.44 | n/a | 3 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | €130.00 → €115.00 | €75.52 | n/a | 9 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | CHF 100.00 | CHF 173.00 | n/a | 1 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $35 | $49.52 | n/a | 1 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $116 | $150.88 | n/a | 1 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $55 | $63.83 | n/a | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,060 → $1,250 | $1,180.16 | n/a | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $130 | $135.84 | n/a | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $58.60 | n/a | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €33.00 → €29.00 | €47.79 | n/a | 17 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 294.00 | kr 183.00 | n/a | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 975.00 | kr 294.70 | n/a | 20 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | 2,630p → 2,845p | 1,640p | n/a | 20 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Sell | CHF 1.30 | CHF 5.92 | n/a | 6 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | kr 1,860 | kr 2,027 | n/a | 12 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €35.00 → €30.00 | €23.90 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 → $27 | $7.78 | n/a | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €23.00 | €9.86 | n/a | 15 | Jan 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 295p | 344p | n/a | 2 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $1.96 | n/a | 2 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €21.00 → €31.60 | €3.45 | n/a | 5 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $31.94 | n/a | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $27.53 | n/a | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 680.00 | CHF 562.60 | n/a | 1 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $13.84 | n/a | 1 | Mar 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $46.34 | n/a | 1 | Mar 19, 2019 |
Sanofi
Apr 20, 2026
Downgraded: Hold
Price Target: $50
Current: $43.72
Upside: +14.36%
Roche Holding AG
Mar 17, 2026
Downgraded: Hold
Price Target: $50
Current: $54.52
Upside: -8.29%
Novo Nordisk
Aug 13, 2025
Upgraded: Hold
Price Target: $61 → $54
Current: $45.89
Upside: n/a
UCB SA
Jun 27, 2025
Maintained: Buy
Price Target: €182.00
Current: €215.55
Upside: n/a
AstraZeneca PLC
Apr 16, 2025
Initiated Coverage: Buy
Price Target: 14,000p → 11,500p
Current: 11,460p
Upside: n/a
GSK plc
Apr 16, 2025
Initiated Coverage: Hold
Price Target: 1,900p → 1,350p
Current: 1,818p
Upside: n/a
Ipsen S.A.
Apr 16, 2025
Initiated Coverage: Hold
Price Target: €100.00
Current: €156.00
Upside: n/a
Merck KGaA
Apr 16, 2025
Initiated Coverage: Sell
Price Target: €190.00 → €107.00
Current: €136.30
Upside: n/a
Roche Holding AG
Apr 16, 2025
Initiated Coverage: Buy
Price Target: CHF 335.00 → CHF 300.00
Current: CHF 355.10
Upside: n/a
Novartis AG
Apr 16, 2025
Initiated Coverage: Buy
Price Target: CHF 97.00 → CHF 95.00
Current: CHF 122.44
Upside: n/a
Apr 16, 2025
Initiated Coverage: Buy
Price Target: €130.00 → €115.00
Current: €75.52
Upside: n/a
Apr 16, 2025
Initiated Coverage: Buy
Price Target: CHF 100.00
Current: CHF 173.00
Upside: n/a
Apr 15, 2025
Initiated Coverage: Hold
Price Target: $35
Current: $49.52
Upside: n/a
Apr 15, 2025
Initiated Coverage: Buy
Price Target: $116
Current: $150.88
Upside: n/a
Oct 25, 2024
Downgraded: Hold
Price Target: $55
Current: $63.83
Upside: n/a
Oct 25, 2024
Maintained: Buy
Price Target: $1,060 → $1,250
Current: $1,180.16
Upside: n/a
Oct 25, 2024
Maintained: Buy
Price Target: $130
Current: $135.84
Upside: n/a
Oct 25, 2024
Maintained: Buy
Price Target: $40
Current: $58.60
Upside: n/a
Oct 17, 2024
Maintained: Hold
Price Target: €33.00 → €29.00
Current: €47.79
Upside: n/a
Oct 1, 2024
Maintained: Buy
Price Target: kr 294.00
Current: kr 183.00
Upside: n/a
Sep 27, 2024
Maintained: Buy
Price Target: kr 975.00
Current: kr 294.70
Upside: n/a
Aug 9, 2024
Rated: Buy
Price Target: 2,630p → 2,845p
Current: 1,640p
Upside: n/a
Jun 21, 2024
Rated: Sell
Price Target: CHF 1.30
Current: CHF 5.92
Upside: n/a
Jun 4, 2024
Maintained: Sell
Price Target: kr 1,860
Current: kr 2,027
Upside: n/a
Apr 17, 2024
Maintained: Hold
Price Target: €35.00 → €30.00
Current: €23.90
Upside: n/a
Mar 1, 2024
Maintained: Buy
Price Target: $34 → $27
Current: $7.78
Upside: n/a
Jan 10, 2024
Maintained: Buy
Price Target: €23.00
Current: €9.86
Upside: n/a
Sep 27, 2023
Maintained: Hold
Price Target: 295p
Current: 344p
Upside: n/a
Jun 8, 2023
Upgraded: Buy
Price Target: n/a
Current: $1.96
Upside: n/a
Jun 8, 2023
Upgraded: Buy
Price Target: €21.00 → €31.60
Current: €3.45
Upside: n/a
Dec 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $31.94
Upside: n/a
Jan 27, 2022
Upgraded: Buy
Price Target: n/a
Current: $27.53
Upside: n/a
Jul 28, 2021
Maintained: Hold
Price Target: CHF 680.00
Current: CHF 562.60
Upside: n/a
Mar 20, 2019
Maintained: Buy
Price Target: n/a
Current: $13.84
Upside: n/a
Mar 19, 2019
Upgraded: Buy
Price Target: n/a
Current: $46.34
Upside: n/a